PT  - JOURNAL ARTICLE
AU  - Jonathon W. Senefeld
AU  - Massimo Franchini
AU  - Carlo Mengoli
AU  - Mario Cruciani
AU  - Matteo Zani
AU  - Ellen K. Gorman
AU  - Daniele Focosi
AU  - Arturo Casadevall
AU  - Michael J Joyner
TI  - COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review
AID  - 10.1101/2022.08.03.22278359
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.08.03.22278359
4099  - http://medrxiv.org/content/early/2022/08/16/2022.08.03.22278359.short
4100  - http://medrxiv.org/content/early/2022/08/16/2022.08.03.22278359.full
AB  - Immunosuppressed patients have increased risk for morbidity and mortality from COVID-19 because they less frequently mount antibody responses to vaccines and often cannot tolerate small-molecule antivirals. The Omicron variant of concern of SARS-CoV-2 has progressively defeated anti-Spike mAbs authorized so far, paving the way to a return to COVID-19 convalescent plasma (CCP) therapy. In this systematic review we performed a metanalysis of 9 controlled studies (totaling 535 treated patients and 1365 controls and including 4 randomized controlled trials), an individual patient data analysis of 125 case reports/series (totaling 265 patients), and a descriptive analysis of 13 uncontrolled large case series without individual patient data available (totaling 358 patients). The metanalysis of controlled studies showed a risk ratio for mortality of 0.65 (risk difference -0.11) in treatment with CCP versus standard of care for immunosuppressed COVID-19 patients. On the basis of this evidence, we encourage initiation of high-titer CCP from vaccinees(‘hybrid plasma’) in immunocompromised patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:PubMed and bioRxiv/medRxiv publicationsI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsCCPCOVID-19 convalescent plasma;nAbneutralizing antibodies;VOCvariant of concern.